Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy
Publication in refereed journal


摘要The tumour microenvironment plays an instrumental role in cancer development, progression and treatment response/resistance. Accumulating evidence is underscoring the fundamental importance of epigenetic regulation in tumour immune evasion. Following many pioneering discoveries demonstrating malignant transformation through epigenetic anomalies (‘epimutations’), there is also a growing emphasis on elucidating aberrant epigenetic mechanisms that reprogramme the milieu of tumour-associated immune and stromal cells towards an immunosuppressive state. Pharmacological inhibition of DNA methylation and histone modifications can augment the efficiency of immune checkpoint blockage, and unleash anti-tumour T-cell responses. However, these non-specific agents also represent a ‘double-edged sword’, as they can also reactivate gene transcription of checkpoint molecules, interrupting immune surveillance programmes. By understanding the impact of epigenetic control on the tumour microenvironment, rational combinatorial epigenetic and checkpoint blockage therapies have the potential to harness the immune system for the treatment of cancer. Copyright © 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
著者Man LIU, Jingying ZHOU, Zhiwei CHEN, Alfred Sze-Lok CHENG
期刊名稱Journal of Pathology
出版社John Wiley & Sons, Ltd
頁次10 - 24
關鍵詞cancer-associated fibroblast, cytotoxic T lymphocyte, dendritic cell, DNA demethylating agents, histone deacetylase inhibitors, macrophage, mesenchymal stem cell, microRNA, myeloid-derived suppressor cell, natural killer cell, regulatory T cell, tumour-associated antigens

上次更新時間 2021-06-01 於 01:11